Published online Mar 6, 2023. doi: 10.12998/wjcc.v11.i7.1627
Peer-review started: December 2, 2022
First decision: December 19, 2022
Revised: January 2, 2023
Accepted: February 2, 2023
Article in press: February 2, 2023
Published online: March 6, 2023
Prostate lymphoma has no characteristic clinical symptomatology, is often misdiagnosed, and currently, clinical case reports of this disease are relatively rare. The disease develops rapidly and is not sensitive to conventional treatment. A delay in the treatment of hydronephrosis may lead to renal function injury, often causing physical discomfort and rapid deterioration with the disease. This paper presents two patients with lymphoma of prostate origin, followed by a summary of the literature concerning the identification and treatment of such patients.
This paper reports on the cases of two patients with prostate lymphoma admitted to the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, one of whom died of the disease 2 mo after diagnosis, while the other was treated promptly, and his tumor was significantly reduced at the 6-mo follow-up.
The literature shows that prostate lymphoma is often seen as a benign prostate disease during its pathogenesis, even though primary prostate lymphoma enlarges rapidly and diffusely with the invasion of surrounding tissues and organs. In addition, prostate-specific antigen levels are not elevated and are not specific. There are no significant features in single imaging either, but during dynamic observation of imaging, it can be found that the lymphoma is diffusely enlarged locally and that systemic symptoms metastasize rapidly. The two cases of rare prostate lymphoma reported herein provide a reference for clinical decision making, and the authors conclude that early nephrostomy to relieve the obstruction plus chemotherapy is the most convenient and effective treatment option for the patient.
Core Tip: Primary prostate lymphoma is extremely rare clinically. Its common pathological type is non-diffuse large b-cell lymphoma, and the mainstream treatment is chemotherapy. However, its diagnosis lacks specific indicators, and delays in treatment due to clinical misdiagnosis often result in adverse events. Early detection of suspicious lesions and provision of appropriate aggressive treatment, such as rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisone, before the continued expansion of the metastatic area has a positive impact on patient prognosis.